270 related articles for article (PubMed ID: 32384283)
1. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
Dulai PS; Battat R; Barsky M; Nguyen NH; Ma C; Narula N; Mosli M; Vande Casteele N; Boland BS; Prokop L; Murad MH; D'Haens G; Feagan BG; Sandborn WJ; Jairath V; Singh S
Am J Gastroenterol; 2020 Jun; 115(6):885-894. PubMed ID: 32384283
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Dulai PS; Singh S; Jairath V; Ma C; Narula N; Vande Casteele N; Peyrin-Biroulet L; Vermeire S; D'Haens G; Feagan BG; Sandborn WJ
Aliment Pharmacol Ther; 2020 Feb; 51(4):435-445. PubMed ID: 31755121
[TBL] [Abstract][Full Text] [Related]
3. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Shaffer SR; Huang E; Patel S; Rubin DT
Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
9. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
10. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
[No Abstract] [Full Text] [Related]
11. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice.
Pauwels RWM; de Vries AC; van der Woude CJ
J Gastroenterol Hepatol; 2020 Nov; 35(11):1893-1901. PubMed ID: 32291796
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
13. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis.
Yong HM; Park SJ; Jeon SR; Park H; Kim HG; Lee TH; Park J; Kim JO; Lee JS; Ko BM; Goong HJ; Park S
Medicine (Baltimore); 2021 Aug; 100(34):e27065. PubMed ID: 34449501
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
Kim ES; Lee HS; Kim SK; Kim EY; Jang BI; Kim KO; Yang CH; Lee YJ;
Scand J Gastroenterol; 2020 Feb; 55(2):163-168. PubMed ID: 31984815
[No Abstract] [Full Text] [Related]
15. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
17. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
19. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]